Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

Search

Search results

BERLIN, 28 August 2020 – Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering…

[Translate to English:]
  • T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
  • Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF

HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).

[Translate to English:]

Newly founded dentalXrai provides a unique, AI-based platform to improve and speed up the analysis of dental X-ray images. Ascenion, technology transfer partner of the Charité – Universitätsmedizin Berlin, holds equity in the start-up.

Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing

[Translate to English:]

Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.

Lead liver disease candidate to enter clinical trials this year

The NUVISAN group, an international service provider for clinical studies, contract development and manufacturing (CRO/CDMO) with headquarters in…

[Translate to English:]

Ascenion’s portfolio company Photonion GmbH offers innovative mass spectrometry systems that allow a more detailed analysis of air pollutants,…

[Translate to English:]

New drug delivery system to enable needle-free application of drugs

Ascenion’s portfolio company Berlin Cures has initiated a Phase IIa clinical study with its lead compound BC 007. The two-armed, randomized,…

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…

Ascenion’s portfolio company OMEICOS dosed a first patient in a Phase II clinical trial for its lead program OMT-28. The placebo-controlled,…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Three months following the first closing of its Series C financing, iThera Medical completed a second closing with Occident Ventures, BayBG and Falk…

Following the successful completion of a Phase I trial with its cardioprotective lead candidate OMT-28, OMEICOS has now closed a Series C financing…

This year’s technology transfer award from Braunschweig’s Chamber of Industry and Commerce goes to scientists at the Helmholtz Centre for Infection…

Ascenion has negotiated a licence agreement between Medical School Hannover (MHH) and its spin-off Cardior Pharmaceuticals providing the company with…

Drug developer Berlin Cures announced the successful completion of its Phase 1 study of its lead candidate BC 007 for the treatment of cardiomyopathy.…

Boost for the first new tuberculosis vaccine in nearly 100 years 

21 August 2018, Munich – Ascenion GmbH, the technology transfer partner of the…

Ascenion’s portfolio company OMEICOS reported positive Phase I data for its lead candidate OMT-28, a small molecule with strong anti-arrhythmic and…

Berlin Cures, one of Ascenion’s portfolio companies, has announced positive Phase I results for its lead candidate BC007 for the treatment of heart…

Making cancer surgery more precise

23 October 2017, Munich – SurgVision BV, a spin-off from the Helmholtz Zentrum München, has been acquired by…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the second closing…

Unique RNA-based approach for the treatment of heart diseases

11 May 2017, Munich – Cardior Pharmaceuticals has completed a EUR 15 million Series A…

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the first closing…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

amcure, a company that received support from Ascenion’s Spinnovator coaching program from the beginning, reports a significant milestone: At the end…

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…

For the first time, a German team has won the world’s biggest life-science start-up competition. Captain T Cell, founded by Dr Felix Lorenz and…

The first clinical trial of MSOT, iThera’s innovative imaging technique, has made it onto the cover of the prestigious journal Science Translational…

amcure, a spin-off from the Karlsruhe Institute of Technology (KIT), has received a further EUR 1.9 million funding from the German Federal Ministry…

Recent Publication in Key Scientific Journal Supports amcure’s Therapeutic Approach in Cancer

Ascenion’s portfolio company OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has received further funding of…

Ascenion takes equity in the MHH start-up Zellkraftwerk

BigChem GmbH was founded this October to commercialize validated IT products and services developed at the Helmholtz Zentrum München. The research was…

As recently announced by Ascenion’s portfolio company Protectimmun, the three parties have agreed that Janssen will financially support preclinical…